Giuliana Grossi

Manufacturing questions delay review of dexmethylphenidate candidate; no safety or efficacy concerns raised.

Martin Hopp, MD, PhD, of Cedars-Sinai Medical Center, and Kate Willis, of Daybreak, explain how undiagnosed sleep disorders can cause depression and anxiety.

Reports highlight gaps in private equity oversight, MA vs FFS outcomes, cancer care access advances, climate health disparities, and uneven genomic testing.

The approval is based on results from MannKind's phase 3 INHALE-1 clinical trial.

Martin Hopp, MD, PhD, of Cedars-Sinai Medical Center, and Kate Willis, of Daybreak, discuss why obstructive sleep apnea is underdiagnosed.

Edgar Chou, MD, explains how oncology teams, primary care, and patients use interoperability to share patient data, improve transitions, and close care gaps.

US health care faces massive shifts: rising ACA deductibles, federal health leadership shakeups, and major care gaps in women's health and dermatology.

Eli Lilly's triple agonist achieved 28.3% weight loss at 80 weeks and 30.3% at 104 weeks, matching bariatric surgery levels.

The Trump administration fired USPSTF leaders, sparking concerns over the future of ACA-mandated free medical screenings and preventive care.

ACA enrollment drops 21.5% in 2026 after enhanced subsidies end. Deductibles hit record $3786 as enrollees shift to high-deductible bronze plans.

A new review links coexisting sleep apnea and diabetes to higher stroke risk, poorer recovery, and greater vascular damage.

Women’s Health Month highlights major 2026 shifts in menopause care, brain health, abortion access, doula coverage, and wearable tech.

Health updates cover abortion pill access, lung care research, pregnancy-linked heart risks, US longevity gaps, and flawed drug adherence metrics.

A cohort-based mortality study found major state-by-state life expectancy gaps, with Southern states lagging in longevity gains.

Scott Shannon, MD, discusses psychedelic therapies, federal policy shifts, and the barriers slowing mental health innovation.

From psychedelics to abortion pills, drug pricing, crisis lines, and cancer care, new policies reshape access—and expose gaps patients still face.

Newly FDA-approved DOR/ISL offers an INSTI-free, 2-drug HIV treatment option with durable suppression and favorable safety.

LXB significantly improved nighttime sleep architecture and daytime symptoms in narcolepsy type 1 and 2, according to phase 4 DUET study results.

Chris Johnson, MBA, discusses how Medicaid incentives and higher primary-care pay can boost preventive pediatric care.

White House projects $600B in savings from MFN drug pricing plan, with major implications for GLP-1 access, Medicaid, and biologics.

A meta-analysis of 26 trials found that IV ketamine rapidly reduced suicidal and depressive symptoms in patients with major depressive episodes.

Shared decision-making and quality of life are increasingly shaping metastatic breast cancer care amid persistent social barriers, notes Hayley Knollman, MD.

New executive order fast-tracks psychedelic therapy research for veterans, but VA rollout, DEA rescheduling, and insurance hurdles still loom.

Philadelphia oncology leaders tackle gaps in biomarker testing, breast cancer advances, myeloma innovation, and clinical trial equity.

This week, a Capitol hearing spotlights Medicare fraud gaps, reports warn of equity setbacks, community oncology boosts survival, and Medicaid work rules loom.

Chris Johnson, MBA, explains how retail-based pediatric clinics and smart tech can expand Medicaid access and streamline visits.

A new Commonwealth Fund report finds persistent racial health disparities nationwide despite coverage gains, with major gaps in care, access, and outcomes.

Newly FDA-approved doravirine/Islatravir maintained HIV suppression in phase 3 trials with comparable safety and minimal metabolic effects.

A 2-week sleep/light intervention shifted teens’ circadian timing earlier, increasing weeknight sleep by about 47 minutes in a randomized trial.

A lengthy Ways and Means Committee hearing revealed extensive Medicare system exploitation and ignited partisan debates on fixing it.